NCT01961349 - Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy | Biotech Hunter

Enrollment

279

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy

Interventions

DRUG

Intralipid

Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)

DRUG

ICI35,868 (Diprivan)

Treated by Anaesthesiologist

DRUG

ICI35,868 (Diprivan) + EES0000645/A (SDS)

Treated by Endoscopist with EES0000645/A(SDS)

Trial Locations (3)

Research Site, Moriya-shi

Research Site, Shinjuku-ku

Research Site, Yokohama